Hearing Loss Disease Treatment Market Size, Share, Growth, Trends | Report 2022-2030
Hearing loss has a serious impact on an individual’s growth and development. According to WHO, globally 430 million people or approximately 5% of the world’s population require attention and action for their hearing disability. Moreover, WHO estimated that by 2050, 2.5 billion people will have some degree of hearing impairment and 700 million people may require rehabilitation in the coming future. Approximately 80% of disease cases belong to low- and middle-income countries. Age has a direct impact on such disabilities and accounts for 25% of auditory impairment in above 60 years of individuals. Thus, an increase in the prevalence of the condition is offering lucrative opportunities for hearing loss disease treatment market growth.
Hearing loss disease treatment market has been mainly segmented on the basis of product as:
A large chunk of disease cases can be prevented through interventions such as community-oriented health education. WHO promotes public awareness through World Hearing Day held every March. However, low- and middle-income countries lack the capacity to implement such interventions effectively. For instance, high-income countries offer evaluation of possible auditory disability in newborns but low- and middle-income countries don’t appear to consider it as an initiative in controlling disease. Therefore, such demographic imbalance is further contributing to the rising prevalence of disease and driving the hearing loss disease treatment market.
The growing research and development in the space are expected to offer better treatment options in coming years. This can be attributed due to the presence of more than 45 therapies under the clinical pipeline at different phases of trials. Some of the pipeline candidates include Frequency Therapeutics’ FX-322, Pipeline Therapeutics’ PIPE 505, Sensorion’s SENS-401, Strekin’s STR001, Otonomy Inc.’s OTO-413, OTO-825, OTO-6XX and OTO-510, and Acousia Therapeutics Gmbh’s ACOU085 and ACOU082 amongst others.
Key market players are taking efforts such as new product launches, collaborations, agreements, regional expansion to maintain their position in market. For example, in July 2022, Astellas Pharma Inc. and Mogrify Limited entered into a collaborative research agreement to develop regenerative medicines in the segment of sensorineural hearing loss. This collaboration will work on the identification of transcription factors that are responsible for cell differentiation to help generate new cochlear hair cells. Astellas Gene Therapies will cover the cost of the research work and also provide its expertise in AAV based genetic medicine. Additionally, in September 2022, Fennec’s drug Pedmark received FDA approval for the treatment of cisplatin-induced ototoxicity in adolescents and children.
Key Players
Market Segmentation
By Product
By Disease Type
By End-user
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hearing Loss Disease Treatment Market
5.1. COVID-19 Landscape: Hearing Loss Disease Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hearing Loss Disease Treatment Market, By Product
8.1. Hearing Loss Disease Treatment Market, by Product, 2022-2030
8.1.1 Devices
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Drugs
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Hearing Loss Disease Treatment Market, By Disease Type
9.1. Hearing Loss Disease Treatment Market, by Disease Type, 2022-2030
9.1.1. Conductive Hearing Loss
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Sensorineural Hearing Loss
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Mixed
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Hearing Loss Disease Treatment Market, By End-user
10.1. Hearing Loss Disease Treatment Market, by End-user, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Otology clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. ambulatory clinics
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Hearing Loss Disease Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck & Co Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline Plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Teva Pharmaceuticals
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Benson Hearing
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. GN Store Nord A/S
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. William Demant Holding A/S
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Medtronic
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Widex USA, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers